JP2021509679A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021509679A5 JP2021509679A5 JP2020537571A JP2020537571A JP2021509679A5 JP 2021509679 A5 JP2021509679 A5 JP 2021509679A5 JP 2020537571 A JP2020537571 A JP 2020537571A JP 2020537571 A JP2020537571 A JP 2020537571A JP 2021509679 A5 JP2021509679 A5 JP 2021509679A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- composition according
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614956P | 2018-01-08 | 2018-01-08 | |
| US62/614,956 | 2018-01-08 | ||
| US201862699345P | 2018-07-17 | 2018-07-17 | |
| US62/699,345 | 2018-07-17 | ||
| PCT/US2019/012228 WO2019136185A1 (en) | 2018-01-08 | 2019-01-03 | Compositions and methods of treating cancer with glycomimetic peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021509679A JP2021509679A (ja) | 2021-04-01 |
| JP2021509679A5 true JP2021509679A5 (https=) | 2022-01-04 |
| JP7390294B2 JP7390294B2 (ja) | 2023-12-01 |
Family
ID=67143977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537571A Active JP7390294B2 (ja) | 2018-01-08 | 2019-01-03 | 糖鎖模倣ペプチドを用いて癌を処置する組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11376307B2 (https=) |
| EP (1) | EP3737365A4 (https=) |
| JP (1) | JP7390294B2 (https=) |
| AU (1) | AU2019205279A1 (https=) |
| CA (1) | CA3086751A1 (https=) |
| WO (1) | WO2019136185A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3086751A1 (en) * | 2018-01-08 | 2019-07-11 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
| EP4181942A4 (en) * | 2020-07-28 | 2024-10-02 | Susavion Biosciences, Inc. | METHOD OF TREATING INFLAMMATORY PATHOLOGIES DRIVEN BY NEUTROPHILS |
| US20250222064A1 (en) * | 2022-03-24 | 2025-07-10 | Wild Boar Biosciences, Llc | Method of treatment of neutrophil-driven inflammatory pathologies |
| US20230364255A1 (en) * | 2020-08-18 | 2023-11-16 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE466069T1 (de) * | 2000-09-05 | 2010-05-15 | Biosight Ltd | Peptid-konjugierte antikrebs-prodrugs |
| US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| CA2566647A1 (en) * | 2004-05-13 | 2005-12-22 | Imclone Systems Incorporated | Inhibition of macrophage-stimulating protein receptor (ron) |
| TW200927761A (en) * | 2007-09-26 | 2009-07-01 | U3 Pharma Ag | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| CN103328496A (zh) | 2010-10-25 | 2013-09-25 | 中央研究院 | 癌靶向肽及其于癌症治疗与诊断的应用 |
| WO2013096829A2 (en) | 2011-12-22 | 2013-06-27 | Arizona Biomedical Research Commission | Activation of cellular assault processes in the treatment of glioblastoma multiforme |
| US20150079071A1 (en) * | 2012-11-30 | 2015-03-19 | The Regents Of The University Of California | Non-catalytic domain targets in matrix metalloprotease proteins for cancer therapies |
| GB201300706D0 (en) * | 2013-01-15 | 2013-02-27 | Cancer Rec Tech Ltd | Antibody |
| US10617755B2 (en) * | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US10011635B2 (en) | 2013-09-27 | 2018-07-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cyclic peptide conjugates and methods of use |
| PL3129067T3 (pl) * | 2014-03-19 | 2023-05-08 | Genzyme Corporation | Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących |
| US9981044B2 (en) * | 2014-08-30 | 2018-05-29 | Susavion Biosciences, Inc. | Activation of adaptive immune processes for the treatment of cancers and infectious diseases |
| WO2016044716A1 (en) * | 2014-09-19 | 2016-03-24 | The American University In Cairo | Nanoparticle-based combinatorial therapy |
| WO2016100679A1 (en) * | 2014-12-19 | 2016-06-23 | Susavion Biosciences, Inc. | Immunotherapy treatments and compositions |
| EP3288576A4 (en) * | 2015-04-27 | 2019-01-16 | Susavion Biosciences, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND PERSISTENT VIRUS INFECTIONS |
| EP3294887A1 (en) * | 2015-05-14 | 2018-03-21 | CNIC Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III | Mirna compositions for the treatment of mature b-cell neoplasms |
| CA3003156C (en) * | 2015-11-06 | 2023-12-05 | Terry Vanden Hoek | Peptides and method for treatment of cardiac arrest |
| ES2987474T3 (es) * | 2016-04-04 | 2024-11-15 | Loxo Oncology Inc | Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida |
| AU2017277288B2 (en) * | 2016-06-09 | 2024-05-16 | Omeros Corporation | Monoclonal antibodies, compositions and methods for detecting mucin -like protein (MLP) as a biomarker for ovarian and pancreatic cancer |
| CA3086751A1 (en) * | 2018-01-08 | 2019-07-11 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
-
2019
- 2019-01-03 CA CA3086751A patent/CA3086751A1/en active Pending
- 2019-01-03 AU AU2019205279A patent/AU2019205279A1/en not_active Abandoned
- 2019-01-03 JP JP2020537571A patent/JP7390294B2/ja active Active
- 2019-01-03 EP EP19735760.1A patent/EP3737365A4/en not_active Withdrawn
- 2019-01-03 WO PCT/US2019/012228 patent/WO2019136185A1/en not_active Ceased
- 2019-01-03 US US16/960,267 patent/US11376307B2/en active Active
-
2022
- 2022-06-27 US US17/850,976 patent/US20220331394A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sandhiya et al. | The dawn of hedgehog inhibitors: Vismodegib | |
| JP2026027329A (ja) | ネクチン－４に特異的な二環コンジュゲート及びその使用 | |
| JP2023130496A (ja) | 癌治療のための併用療法 | |
| JP2021509679A5 (https=) | ||
| KR20240110996A (ko) | 면역 관문 저해제와 조합한 플리나불린의 용도 | |
| EP3053578B1 (en) | Combination cancer therapy using azabicyclo compound | |
| TW201107327A (en) | Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent | |
| Ma et al. | The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation | |
| TW202228724A (zh) | 以反轉錄酶抑制劑治療癌症之方法 | |
| EP3735267A1 (en) | Methods for treating colorectal and metastatic colorectal cancers | |
| JP2022508935A (ja) | がん治療における免疫モジュレーションのための組合せ | |
| CN119816313A (zh) | 含有抗人表皮生长因子受体2（her2）嵌合抗原受体（car）的自然杀伤细胞的给药方法 | |
| CN108498802A (zh) | 用于治疗非小细胞肺癌的药物组合物及其制剂 | |
| Qin et al. | CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies | |
| CN112584842A (zh) | 使用锌剂的肿瘤治疗 | |
| Hwang et al. | Emerging egfr-targeted therapy in head and neck cancer: A review | |
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| EP4309658A1 (en) | Anti-tumor combined preparation comprising hydroxyprogesterone caproate and use thereof | |
| US20230116137A1 (en) | Methods for treating colorectal and metastatic colorectal cancers | |
| US20240277804A1 (en) | Triple combination therapy | |
| Yi et al. | Immunotherapy of triple-negative breast cancer | |
| CN114225023B (zh) | 抗csf-1r抗体联合抗pd-l1抗体的应用 | |
| JPWO2020257536A5 (https=) | ||
| TW202304512A (zh) | 雙特異性t細胞銜接體之給藥 | |
| CA3250299A1 (en) | CANCER TREATMENT |